Who makes Single dose of PF-07220060 as second Tablet Formulation?

Single dose of PF-07220060 as second Tablet Formulation is developed by Pfizer.

What development phase is Single dose of PF-07220060 as second Tablet Formulation in?

Single dose of PF-07220060 as second Tablet Formulation is in Phase 1.

Last reviewed 2026-05-13 · How we verify

Single dose of PF-07220060 as second Tablet Formulation

Pfizer · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	Single dose of PF-07220060 as second Tablet Formulation
Also known as	Cohort 2, second Tablet Formulation, Fasted, Cohort 4, second Tablet Formulation, Second Dose level, Fasted
Sponsor	Pfizer
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Single dose of PF-07220060 as second Tablet Formulation CI brief — competitive landscape report
Single dose of PF-07220060 as second Tablet Formulation updates RSS · CI watch RSS
Pfizer portfolio CI